Report: In Vitro Diagnostics Market Analysis 2009-2024 TOC

1.1 Focus of this Report
- 1.1.1 This Report Discusses IVD Tests According to Applications
- 1.1.2 How Companies are Discussed
- 1.1.3 Forecasts Include Laboratory-Only Companies
1.2 Crucial Points
- 1.2.1 Worldwide IVD Market Will Grow Well for the Next 15 Years
- 1.2.2 Short-Term Growth Led by Pregnancy, Influenza and Oncology Tests
- 1.2.3 SWOT Analysis
1.3 Aim, Scope and Format of this Report
- 1.3.1 Chapter Outlines
1.4 Research Methods

2.1 What Are IVD Tests?
- 2.1.1 Biomarkers
2.2 How IVDs are Regulated by the FDA
2.3 Types of IVD Tests
2.4 Diagnostics Historically Separate from Pharmacological Treatment
2.5 Relative Costs of IVDs
2.6 Point of Care Tests (POCTs)
- 2.6.1 POCTs and Hospital Stays
- 2.6.2 What Home POCTs Say About the IVD Market
2.7 Laboratory IVD Tests versus Point of Care Testing
- 2.7.1 Diagnosis Turnover Rates
- 2.7.2 How Quickly Are Results Needed?
- 2.7.3 How Much do Shorter Turnaround Times Improve Treatment?
- 2.7.4 Economies of Scale

4.1 Genetic Tests: Medicine of the Future?
- 4.1.1 Genetic Tests and Tailored Medicine
4.2 Market Forecast, 2009-2024
4.3 2009 Call for Genetic Test Standards
4.4 Genetics and Oncology
- 4.4.1 BRCA1 and BRCA2 Genetic Tests
- 4.4.2 Genetics and HER2: Success Story
- 4.4.3 HER2 and Cancer: How IVDs and Therapy Interconnect
- 4.4.4 Genetics and Response to Gleevec for Gastrointestinal Cancer
4.5 Genetics and Statins
- 4.5.1 Celera' s Genetic Test for Statin Responsiveness: the KIF6 Allele
- 4.5.2 Interview with Thomas White, PhD, Chief Scientific Officer and VP of Research, Celera
4.6 Genetic Test Companies
- 4.6.1 Myriad Genetics
- 4.6.2 deCODE Genetics
- 4.6.3 23andMe
- 4.6.4 Navigenics
4.7 Market by Region: Forecast Discussion
- 4.7.1 US
- 4.7.2 Japan and China
- 4.7.3 Europe

5.1 How Cancer is Diagnosed: Currently and in the Future
5.2 Market Forecast: 2009-2024
5.3 Lung Cancer
- 5.3.1 Almac Diagnostics
- 5.3.2 Lung Cancer IVD: Worldwide Unmet Need
5.4 Prostate Cancer
- 5.4.1 Gen-Probe Incorporated
- 5.4.2 Gen-Probe and DiagnoCure Incorporated
- 5.4.3 Timeline for a PCA3 Point of Care Test
5.5 Colorectal Cancer
- 5.5.1 Quest Diagnostics
- 5.5.2 DiagnoCure Inc.: Molecular Diagnostics for Cancer
- 5.5.3 Aventir Biotech LLC: First FDA-Approved Faecal Occult Blood Test
- 5.5.4 Alpha Laboratories
5.6 Human Papillomavirus (HPV) and Cervical Cancer
- 5.6.1 Digene/Qiagen
- 5.6.2 Cytyc and Hologic

6.1 Brief Overview of Diabetes
6.2 Market Forecast, 2009-2024
6.3 Glucose IVD Market by Subdivision: Diagnostic Tests and Monitoring Devices
6.4 Types of Tests
- 6.4.1 Blood Tests
- 6.4.2 Urine Tests
6.5 Diabetes IVD Assessment Targets
- 6.5.1 Ketones
- 6.5.2 Microalbuminurea
- 6.5.3 Glucose
6.6 Top Diabetes IVD Companies
- 6.6.1 Lifescan/Johnson & Johnson
- 6.6.2 Roche
- 6.6.3 Abbott
- 6.6.4 Bayer Diagnostics
- 6.6.5 Home Diagnostics, Inc.
6.7 Immediate Results: Crucial for Glucose Monitoring and Point of Care Testing
6.8 Future Opportunities in the Diabetes/Glucose IVD Market
6.9 Market by Region: Forecast Discussion
- 6.9.1 India and China
- 6.9.2 United States
- 6.9.3 Europe

7.1 Market Forecast, 2009-2024
7.2 Cholesterol Testing Companies
- 7.2.1 Polymer Technology Systems (PTS)
- 7.2.2 Roche Diagnostics
- 7.2.3 Home Access Health Corporation
- 7.2.4 Atherotech, Inc.
7.3 Market by Region: Forecast Discussion
- 7.3.1 Europe
- 7.3.2 US
- 7.3.3 India
- 7.3.4 South America

8.1 Market Forecast, 2009-2024
8.2 OTC HIV Tests: The Debate
- 8.2.1 Home Testing vs. Home Sampling
- 8.2.2 Home Tests and Home Results Not Approved
8.3 HIV Testing Companies
- 8.3.1 Home Access Health Corporation
- 8.3.2 OraSure Technologies
- 8.3.3 MedMira
- 8.3.4 Novartis/Chiron
8.4 Market by Region: Forecast Discussion
- 8.4.1 Europe
- 8.4.2 US
- 8.4.3 Asia
- 8.4.4 Africa: Where the HIV Problem is Worst

9.1 Market Forecast, 2009-2024
9.2 Test Targets
9.3 Typing: A and B Strains
- 9.3.1 Rapid Tests: 15 Minutes or Less
9.4 Rapid Test Companies
- 9.4.1 Becton, Dickinson and Company
- 9.4.2 Inverness Medical Innovations, Inc.
- 9.4.3 Quidel
- 9.4.4 SA Scientific, Ltd.
- 9.4.5 Meridian Bioscience, Inc.
9.5 2009 Swine Flu as Case Study
9.6 Avian Flu: H5N1
- 9.6.1 IVD Market Forecast and Avian Flu
- 9.6.2 Avian Flu Tests
- 9.6.3 Arbor Vita Corporation
9.7 Market by Region: Forecast Discussion
- 9.7.1 US
- 9.7.2 Japan: The Second-Largest Flu Market
- 9.7.3 Europe
- 9.7.4 Hong Kong: Site of Original Avian Flu Outbreak in Human Beings
- 9.7.5 Sites of Recent Avian Flu Outbreaks

10.1 Market Forecast
10.2 Types of Tests: Individual and Multiple Assays
10.3 OTC Test Companies
- 10.3.1 Inverness Medical Innovations/First Check Diagnostics
- 10.3.2 BTNX Inc.
- 10.3.3 Phamatech
- 10.3.4 Alfa Scientific
- 10.3.5 ACON Laboratories/Inverness Medical Innovations
10.4 Market by Region: Forecast Discussion
- 10.4.1 US
- 10.4.2 Europe: The European Workplace Drug Testing Society

11.1 Market Forecast
11.2 Male and Fertility Tests: Relative Sales
11.3 Over-the-Counter Tests: The Largest Market?
- 11.3.1 Pregnancy Tests
- 11.3.2 Ovulation Tests: As Contraceptive and Pro-Conception Tools
- 11.3.3 Female Fertility Tests
- 11.3.4 Male Fertility Tests: Improving Products
11.4 OTC Test Companies
- 11.4.1 Church & Dwight Co, Inc.
- 11.4.2 Swiss Precision Diagnostics: Inverness Medical Innovations and Procter & Gamble
- 11.4.3 Johnson & Johnson
- 11.4.4 Genosis PLC/The LifeStyle Company
11.5 Market by Region: Forecast Discussion
- 11.5.1 US
- 11.5.2 Europe
- 11.5.3 Japan
- 11.5.4 South America

12.1 Most IVD Test Markets are Growth Markets
12.2 Growth Drivers
- 12.2.1 The Greatest Unmet IVD Need
12.3 Growth-Limiting Factors
- 12.3.1 Growth-Limiting Factors for Specific Markets
- 12.3.2 Saturated Markets
12.4 Over the Counter Tests: The Added Value of Convenience
12.5 Diagnostic Innovation: Improving the Future of Medicine

In Vitro Diagnostics Market Analysis 2009-2024